Physician profile
Vidhya Gunasekaran
NPI 1467039735
$282.47
in general payments reported to CMS, 2019-2025
9 companies · $96.47 in 2025
The $96.47 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $84.06 · 2024: $102 · 2025: $96.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $78.87 | 2024-2025 | Voyxact, Jynarque |
| Aurinia Pharma U.S., INC. | $62.28 | 2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $38.89 | 2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $21.79 | 2023 | Segluromet, Steglujan, Steglatro |
| Merz Pharmaceuticals, LLC | $18.37 | 2024 | Xeomin |
| Xeris Pharmaceuticals, INC. | $17.74 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $15.36 | 2023 | |
| Amneal Pharmaceuticals LLC | $14.98 | 2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.19 | 2023 | Synjardy, Jardiance, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Gunasekaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.